Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy

Kawaguchi, Yukiko; Saito, Bungo; Nakata, Ayaka; Matsui, Tomoharu; Sasaki, Yohei; Shimada, Shotaro; Abe, Maasa; Watanuki, Megumi; Baba, Yuta; Murai, So; Arai, Nana; Fujiwara, Shun; Kabasawa, Nobuyuki; Tsukamoto, Hiroyuki; Uto, Yui; Yanagisawa, Kouji; Hattori, Norimichi; Harada, Hiroshi; Nakamaki, Tsuyoshi

doi:10.1007/s12185-020-02910-0

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ITGA1 is an integrin upregulated by the B-lymphocytes of follicular lymphoma when cultured with follicular dendritic cells (FDCs); it is an important molecule necessary for the cell-matrix adhesion and the pathogenesis of follicular lymphoma [26]. Elevated CRP is associated with poor prognosis in follicular lymphoma [27]. ARG1 expression defines immunosuppressive subsets of tumor-associated macrophages [28], and macrophages contribute to follicular lymphoma pathogenesis [29].…”

Section: Discussionmentioning

confidence: 99%

Artificial Neural Network Analysis of Gene Expression Data Predicted Non-Hodgkin Lymphoma Subtypes with High Accuracy

Carreras

Hamoudi

2021

MAKE

View full text Add to dashboard Cite

Predictive analytics using artificial intelligence is a useful tool in cancer research. A multilayer perceptron neural network used gene expression data to predict the lymphoma subtypes of 290 cases of non-Hodgkin lymphoma (GSE132929). The input layer included both the whole array of 20,863 genes and a cancer transcriptome panel of 1769 genes. The output layer was lymphoma subtypes, including follicular lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and marginal zone lymphoma. The neural networks successfully classified the cases consistent with the lymphoma subtypes, with an area under the curve (AUC) that ranged from 0.87 to 0.99. The most relevant predictive genes were LCE2B, KNG1, IGHV7_81, TG, C6, FGB, ZNF750, CTSV, INGX, and COL4A6 for the whole set; and ARG1, MAGEA3, AKT2, IL1B, S100A7A, CLEC5A, WIF1, TREM1, DEFB1, and GAGE1 for the cancer panel. The characteristic predictive genes for each lymphoma subtypes were also identified with high accuracy (AUC = 0.95, incorrect predictions = 6.2%). Finally, the topmost relevant 30 genes of the whole set, which belonged to apoptosis, cell proliferation, metabolism, and antigen presentation pathways, not only predicted the lymphoma subtypes but also the overall survival of diffuse large B-cell lymphoma (series GSE10846, n = 414 cases), and most relevant cancer subtypes of The Cancer Genome Atlas (TCGA) consortium including carcinomas of breast, colorectal, lung, prostate, and gastric, melanoma, etc. (7441 cases). In conclusion, neural networks predicted the non-Hodgkin lymphoma subtypes with high accuracy, and the highlighted genes also predicted the survival of a pan-cancer series.

show abstract

Section: Discussionmentioning

confidence: 99%

Artificial Neural Network Analysis of Gene Expression Data Predicted Non-Hodgkin Lymphoma Subtypes with High Accuracy

Carreras

Hamoudi

2021

MAKE

View full text Add to dashboard Cite

show abstract

“…It also promotes angiogenesis following the infiltration of tumor-associated macrophages ( 39 ). SAA1, SAA2, and CRP participate in the acute phase response ( 40 ). The upregulation of CRP is associated with a poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy ( 40 ) and may indicate immunochemotherapy-related interstitial lung disease in B-cell lymphoma ( 41 ).…”

Section: Resultsmentioning

confidence: 99%

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Lou¹,

Wang²,

Wang³

et al. 2023

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

“…Changes in inflammatory status in patients with cancer, as a result of changes in the tumor microenvironment and APP components, have been shown to predict the duration of remission and disease survival in a variety of solid tumors and lymphoid malignancies [11,15]. The relationship between cancer and APP has been studied in human and veterinary medicine, with a particular focus on a positive correlation between CRP concentration and clinical manifestations of lymphoid neoplasia at the time of diagnosis [16][17][18]. However, advances in diagnostic assessment for dogs with disseminated lymphoma have yet to be fully investigated.…”

Section: Discussionmentioning

confidence: 99%

Impact of serum C-reactive protein level as a biomarker of cancer dissemination in canine lymphoid neoplasia

et al. 2022

View full text Add to dashboard Cite

Background and Aim: C-reactive protein (CRP) is a highly sensitive but non-specific acute phase protein that has been widely used to predict the biological behavior of patients with cancer. This study aimed to examine the significance of the serum CRP biomarker in predicting the prognosis of dogs with lymphoma. Materials and Methods: Blood samples (5 mL) were collected from 34 lymphoma dogs and control healthy dogs. Canine lymphoma clinical staging was classified using the World Health Organization (WHO) criteria. All lymphoma dogs were reclassified into two groups based on the disease stage. Stages IV and V were designated as advanced stages, and Stages I–III were designated as other stages. The serum CRP level was then determined using a commercial canine CRP fluorescent immunoassay kit and routine hematological and biochemical analyses. C-reactive protein levels, circulating inflammatory parameters, such as neutrophil-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, and platelet-to-lymphocyte ratio, and albumin levels were compared between advanced stages (IV and V) and Stages I to III using Mann–Whitney U tests. Receiver operating characteristic (ROC) curves were also generated to determine the cutoff value, diagnostic sensitivity, and specificity of the CRP level. Results: A prospective study identified 34 dogs recently diagnosed with canine lymphoma. C-reactive protein levels were significantly higher in lymphoma dogs in advanced stages (IV and V) than in lymphoma dogs in Stages I–III. According to the ROC curve analysis, a CRP cutoff level of 54.1 mg/L indicates advanced-stage canine lymphoma, which can be used as a biomarker to predict cancer dissemination. Conclusion: Serum CRP concentrations can assist clinical decision-making on the WHO stage in lymphoma dogs in clinical applications. The limitations of this study include a small number of lymphomas and no survival analysis.

show abstract

Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy

Cited by 6 publications

References 30 publications

Artificial Neural Network Analysis of Gene Expression Data Predicted Non-Hodgkin Lymphoma Subtypes with High Accuracy

Artificial Neural Network Analysis of Gene Expression Data Predicted Non-Hodgkin Lymphoma Subtypes with High Accuracy

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma

Impact of serum C-reactive protein level as a biomarker of cancer dissemination in canine lymphoid neoplasia

Contact Info

Product

Resources

About